Insider Selling: RxSight, Inc. (NASDAQ:RXST) Director Sells 7,000 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares of the company’s stock, valued at approximately $637,428.03. This trade represents a 22.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

RxSight Stock Up 2.5 %

Shares of RXST stock opened at $25.84 on Friday. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -31.13 and a beta of 1.22. RxSight, Inc. has a 12-month low of $24.64 and a 12-month high of $66.54. The firm has a fifty day moving average of $30.56 and a 200-day moving average of $41.20.

RxSight (NASDAQ:RXST) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The business had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. Research analysts expect that RxSight, Inc. will post -0.7 earnings per share for the current year.

Institutional Trading of RxSight

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of RxSight by 17.7% in the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock valued at $40,398,000 after buying an additional 122,775 shares during the period. Victory Capital Management Inc. lifted its position in RxSight by 21.0% in the 3rd quarter. Victory Capital Management Inc. now owns 259,864 shares of the company’s stock valued at $12,845,000 after acquiring an additional 45,161 shares in the last quarter. Baillie Gifford & Co. boosted its stake in RxSight by 17.0% in the 3rd quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock worth $20,711,000 after purchasing an additional 60,789 shares during the period. Barclays PLC increased its holdings in RxSight by 389.8% during the 3rd quarter. Barclays PLC now owns 58,786 shares of the company’s stock worth $2,906,000 after purchasing an additional 46,783 shares in the last quarter. Finally, State Street Corp raised its stake in shares of RxSight by 8.3% in the 3rd quarter. State Street Corp now owns 817,671 shares of the company’s stock valued at $40,417,000 after purchasing an additional 62,349 shares during the period. 78.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. UBS Group began coverage on shares of RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 price objective for the company. JPMorgan Chase & Co. cut their price target on RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price objective on shares of RxSight in a research note on Wednesday, February 26th. Stifel Nicolaus dropped their target price on shares of RxSight from $35.00 to $33.00 and set a “hold” rating for the company in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company reduced their price target on RxSight from $40.00 to $35.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.